These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38042696)

  • 1. Supporting evidence-based rotavirus vaccine introduction decision-making and implementation: Lessons from 8 Gavi-eligible countries.
    Jennings MC; Sauer M; Manchester C; Soeters HM; Shimp L; Hyde TB; Parashar U; Burgess C; Castro B; Hossein I; Othepa M; Payne DC; Tate JE; Walldorf J; Privor-Dumm L; Richart V; Santosham M;
    Vaccine; 2024 Jan; 42(1):8-16. PubMed ID: 38042696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of rotavirus vaccine use in Asia and the Pacific regions: challenges and future prospects.
    Buchy P; Chen J; Zhang XH; Benninghoff B; Lee C; Bibera GL
    Expert Rev Vaccines; 2021 Dec; 20(12):1499-1514. PubMed ID: 33275065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global rotavirus vaccine introductions and coverage: 2006 - 2016.
    Abou-Nader AJ; Sauer MA; Steele AD; Tate JE; Atherly D; Parashar UD; Santosham M; Nelson EAS
    Hum Vaccin Immunother; 2018; 14(9):2281-2296. PubMed ID: 29787334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030.
    Atherly DE; Lewis KD; Tate J; Parashar UD; Rheingans RD
    Vaccine; 2012 Apr; 30 Suppl 1():A7-14. PubMed ID: 22520139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health Impact of Rotavirus Vaccination in Developing Countries: Progress and Way Forward.
    Parashar UD; Johnson H; Steele AD; Tate JE
    Clin Infect Dis; 2016 May; 62 Suppl 2(Suppl 2):S91-5. PubMed ID: 27059361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health and economic impact of rotavirus vaccination in GAVI-eligible countries.
    Kim SY; Sweet S; Slichter D; Goldie SJ
    BMC Public Health; 2010 May; 10():253. PubMed ID: 20470426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health economics of rotavirus immunization in Vietnam: potentials for favorable cost-effectiveness in developing countries.
    Tu HA; Rozenbaum MH; Coyte PC; Li SC; Woerdenbag HJ; Postma MJ
    Vaccine; 2012 Feb; 30(8):1521-8. PubMed ID: 22119590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential impact and cost-effectiveness of rotavirus vaccination in Afghanistan.
    Anwari P; Debellut F; Pecenka C; Parwiz SM; Clark A; Groman D; Safi N
    Vaccine; 2018 Dec; 36(51):7769-7774. PubMed ID: 29107346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of rotavirus vaccines in Sub-Saharan African countries.
    Mwenda JM; Parashar UD; Cohen AL; Tate JE
    Vaccine; 2018 Nov; 36(47):7119-7123. PubMed ID: 29914848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re-evaluating the potential impact and cost-effectiveness of rotavirus vaccination in 73 Gavi countries: a modelling study.
    Debellut F; Clark A; Pecenka C; Tate J; Baral R; Sanderson C; Parashar U; Kallen L; Atherly D
    Lancet Glob Health; 2019 Dec; 7(12):e1664-e1674. PubMed ID: 31708147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of geographic and economic heterogeneity on rotavirus diarrhea burden and vaccination impact and cost-effectiveness in the Lao People's Democratic Republic.
    Rheingans R; Anderson JD; Bagamian KH; Pecenka CJ
    Vaccine; 2018 Dec; 36(51):7868-7877. PubMed ID: 30007827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re-evaluating the cost and cost-effectiveness of rotavirus vaccination in Bangladesh, Ghana, and Malawi: A comparison of three rotavirus vaccines.
    Pecenka C; Debellut F; Bar-Zeev N; Anwari P; Nonvignon J; Shamsuzzaman M; Clark A
    Vaccine; 2018 Nov; 36(49):7472-7478. PubMed ID: 30420039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress in the introduction of rotavirus vaccine--Latin America and the Caribbean, 2006-2010.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 Dec; 60(47):1611-4. PubMed ID: 22129995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The composition of demand for newly launched vaccines: results from the pneumococcal and rotavirus vaccine introductions in Ethiopia and Malawi.
    Williams BA; Kidane T; Chirwa G; Tesfaye N; Prescott MR; Scotney ST; Valle M; Abebe S; Tambuli A; Malewezi B; Mohammed T; Kobayashi E; Wootton E; Wong R; Dosani R; Subramaniam H; Joseph J; Yavuz E; Apple A; Le Tallec Y; Kang'ethe A
    Health Policy Plan; 2016 Jun; 31(5):563-72. PubMed ID: 26856361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rotavirus vaccines: targeting the developing world.
    Glass RI; Bresee JS; Turcios R; Fischer TK; Parashar UD; Steele AD
    J Infect Dis; 2005 Sep; 192 Suppl 1():S160-6. PubMed ID: 16088799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An overview of rotavirus vaccination programs in developing countries.
    Hallowell BD; Tate J; Parashar U
    Expert Rev Vaccines; 2020 Jun; 19(6):529-537. PubMed ID: 32543239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the potential economic and health impact of rotavirus vaccination in 63 middle-income countries not eligible for Gavi funding: a modelling study.
    Debellut F; Clark A; Pecenka C; Tate J; Baral R; Sanderson C; Parashar U; Atherly D
    Lancet Glob Health; 2021 Jul; 9(7):e942-e956. PubMed ID: 33891885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is rotavirus still a major cause for diarrheal illness in hospitalized pediatric patients after rotavirus vaccine introduction in the Saudi national immunization program?
    Hegazi MA; Sayed MH; Sindi HH; Bekhit OE; El-Deek BS; Alshoudri FMY; Noorelahi AK
    Medicine (Baltimore); 2017 Apr; 96(15):e6574. PubMed ID: 28403085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remaining issues and challenges for rotavirus vaccine in preventing global childhood diarrheal morbidity and mortality.
    Tate JE; Patel MM; Cortese MM; Lopman BA; Gentsch JR; Fleming J; Steele AD; Parashar UD
    Expert Rev Vaccines; 2012 Feb; 11(2):211-20. PubMed ID: 22309669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of rotavirus vaccination in children under five years of age in 195 countries: A meta-regression analysis.
    Janko MM; Joffe J; Michael D; Earl L; Rosettie KL; Sparks GW; Albertson SB; Compton K; Pedroza Velandia P; Stafford L; Zheng P; Aravkin A; Kyu HH; Murray CJL; Weaver MR
    Vaccine; 2022 Jun; 40(28):3903-3917. PubMed ID: 35643565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.